GILD Nov 2024 50.000 put
| Previous Close | 0.1600 |
| Open | 0.0700 |
| Bid | 0.0500 |
| Ask | 0.5700 |
| Strike | 50.00 |
| Expire Date | 2024-11-15 |
| Day's Range | 0.0700 - 0.1600 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 271 |
Business WireGilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
FOSTER CITY, Calif., October 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced additional data from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752) providing an overview of the efficacy and safety of twice-yearly lenacapavir, the company’s injectable HIV-1 capsid inhibitor, for the investigational use of HIV prevention among a broad and geographically diverse range of cisgender men and gender-diverse people.
Simply Wall St.Gilead Sciences' (NASDAQ:GILD) investors will be pleased with their favorable 62% return over the last five years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore...
ZacksPraxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
